Article Text

Download PDFPDF
Systematic review and meta-analysis
Cardiac resynchronisation therapy reduces mortality in patients with heart failure but questions remain
  1. Matthew Luckie1,
  2. Rajdeep S Khattar1
  1. 1Manchester Heart Centre, Manchester Royal Infirmary and The University of Manchester, Manchester, UK
  1. Correspondence to Rajdeep S Khattar
    Manchester Heart Centre, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, UK; rskhattar{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


Cardiac resynchronisation therapy (CRT) is now a well-established therapy for certain subgroups of patients with heart failure, with a large body of evidence demonstrating improvement in symptoms and beneficial changes in cardiac structure and function. American and European guidelines support its use in patients with New York Heart Association (NYHA) class III and IV heart failure, prolonged QRS duration and left ventricular ejection fraction <35%. The COMPANION trial1 demonstrated an all-cause mortality benefit of CRT when combined with implantable cardioverter defibrillator (ICD) therapy in this subgroup, and, subsequently, the CARE-HF trial2 established a mortality benefit attributable to CRT alone when compared with optimal medical therapy (OMT). More recently, the REVERSE3 and MADIT-CRT4 trials in patients with less severe, NYHA …

View Full Text


  • Competing interests None.